Amryt, a global, commercial-stage biopharmaceutical company dedicated to commercializing and developing novel therapeutics to treat patients suffering from serious and life-threatening rare diseases, ...

Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced ...

Amryt’s AP101 EASE Phase III trial has been extended to include infants aged 21 days to four years. Amryt’s AP101 EASE Phase III trial has been extended to include infants aged 21 days to four years, ...

Amryt, a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases, today announces that the U.S.

Amryt, the pharmaceutical company focused on best-in-class treatments for rare and orphan diseases, is pleased to announce the commencement of "EASE", its Phase 3 clinical trial of AP101, Amryt's lead ...

Biopharmaceutical company Amryt Pharma is seeking to raise €15 million to fund clinical trials for the treatment of a rare, genetic skin disorder. The company, which focuses on rare and orphan ...

Pharma firm Amryt to start Phase 3 Clinical Trial of drug to treat “devastating disorder” Amryt Pharma has announced the commencement of “EASE”, the Phase 3 clinical trial of AP101, which offers a ...

UK-based specialist Amryt Pharma is looking to expand in 2018 after acquiring two rare disease treatments. A relative newcomer to the niche rare disease market, Amryt Pharma was founded by former ...